Natasha B Leighl

Natasha B Leighl, BSc, MSc, MD

  • Lung cancer therapy including novel compounds and early phase trials
  • Breast cancer therapeutics including novel compounds and early phase trials
  • Health services research
  • Economics of lung cancer therapy
  • Treatment decision-making in advanced cancer, including development of patient decision aids
  • Patient-physician communication
Clin Lung Cancer. 2016 Jul 9;
Wong KM, Ding K, Li S, Bradbury P, Tsao MS, Der SD, Shepherd FA, Chung C, Ng R, Seymour L, Leighl NB
Oncologist. 2016 Jul 22;
Hannon B, Swami N, Pope A, Leighl N, Rodin G, Krzyzanowska M, Zimmermann C
Curr Oncol. 2016 Jun;23(3):178-83
Sung MR, Ellis PM, Verma S, Duncan E, Leighl NB
J Thorac Oncol. 2016 Apr;11(4 Suppl):S134
Zer A, Hershko-Klement A, Hwang D, Korpanty G, Leighl N, Liu G, Feld R, Burkes R, Tsao M, Shepherd F
Eur J Cancer. 2016 May 4;61:85-93
MacDonald KV, Bombard Y, Deal K, Trudeau M, Leighl N, Marshall DA
CMAJ. 2016 Apr 18;
Zimmermann C, Swami N, Krzyzanowska M, Leighl N, Rydall A, Rodin G, Tannock I, Hannon B
Oncotarget. 2016 Mar 25;
Sacher AG, Le LW, Lara-Guerra H, Waddell TK, Sakashita S, Chen Z, Kim L, Zhang T, Kamel-Reid S, Salvarrey A, Darling G, Yasufuku K, Keshavjee S, De Perrot M, Shepherd FA, Liu G, Tsao M, Leighl NB


Associate Professor, Department of Medicine, University of Toronto
President, Lung Cancer Canada
Chair, Working Group on Economic Analysis, National Cancer Institute of Canada Clinical Trials Group​